US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% META $720.89 ▼-0.06% SPCX $160.57 ▼-4.19%
FinancialContent

Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

0.6501 +0.0266 (+4.27%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
A Preview Of Lucid Diagnostics's Earnings ↗
 
Via Benzinga
News headline image
Why PAVmed Shares Are Falling Today ↗
PAVmed Inc. (NASDAQ: PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures. 
Via Benzinga
News headline image
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
PAVmed and Lucid Diagnostics Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 11, 2022 ↗
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. 
Via Benzinga
News headline image
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
News headline image
PAVmed Partners with Novosound on Ultrasound Imaging Technology
From PAVmed Inc.
Via Business Wire
News headline image
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
Via Benzinga
News headline image
Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO
From PAVmed Inc.
Via Business Wire
News headline image
Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
From Lucid Diagnostics Inc.
Via Business Wire
News headline image
How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock? ↗
Lucid Diagnostics Inc. - Common Stock's (NASDAQ:LUCD) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 378.70 thousand... 
Via Benzinga
News headline image
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
From Lucid Diagnostics Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >